Is Platelet-Rich Plasma (PRP) Approved by the FDA?

PRP itself has never received FDA approval for any specific therapeutic use, but that does not mean it is illegal or unregulated. The distinction matters: the FDA has cleared the devices that prepare PRP through a streamlined pathway, while the clinical injection of PRP into a knee, scalp, or tendon happens legally as an off-label procedure. This regulatory gray zone is why you can walk into a clinic tomorrow and get a PRP injection even though no federal agency has formally endorsed it for your condition.

What “FDA Cleared” Actually Means for PRP

The FDA’s Center for Biologics Evaluation and Research (CBER) oversees blood products, and PRP falls into that category. Under the Code of Federal Regulations, certain blood products like PRP are exempt from the traditional approval pathway that requires animal studies and phased clinical trials. Instead, the machines that spin your blood and concentrate the platelets reach the market through what is called a 510(k) clearance. That pathway lets a manufacturer show its device is “substantially equivalent” to one already on the market, and then it can be sold.

Here is the catch: nearly all of those 510(k)-cleared PRP systems were approved specifically for producing platelet-rich preparations to be mixed with bone graft materials in orthopedic surgery, improving how bone grafts handle. That is a narrow, specific use. When a doctor injects PRP into your arthritic knee, your thinning scalp, or your torn rotator cuff, they are using a cleared device for a purpose the FDA never reviewed. The device is legal. The injection protocol is legal. But no one at the FDA has evaluated whether PRP actually works for any of those conditions.

How Off-Label Use Works in Practice

Off-label use is extremely common across medicine. Physicians regularly prescribe drugs and use devices for purposes beyond their original approved indication, and this is perfectly legal. PRP is no different. Because the preparation systems carry 510(k) clearance, and because PRP is derived from a patient’s own blood rather than manufactured in a factory, clinicians can legally offer it for a wide range of musculoskeletal and cosmetic conditions.

The practical consequence is that the burden of evaluating whether PRP is appropriate for a given condition falls largely on the treating physician and, to a real extent, on you. Insurance companies typically do not cover PRP injections for most indications, precisely because the FDA has not formally approved them. Out-of-pocket costs vary widely depending on the clinic, the body part being treated, and how many sessions are recommended, but the lack of FDA approval for specific uses is the main reason your insurance plan is unlikely to pick up the tab.

What PRP Actually Does in the Body

PRP works by concentrating the platelets from your blood to levels well above what normally circulates. Platelets are not just clotting agents; they contain small packets called alpha granules loaded with growth factors. When injected into damaged tissue, those platelets release growth factors that promote blood vessel formation, support the production of new structural tissue, and modulate the local immune environment.

The elevated platelet concentration is meant to accelerate and amplify the body’s normal repair processes with minimal side effects. In theory, the local burst of growth factors and signaling molecules mimics what happens during natural wound healing but in a more concentrated dose.

⁴

This biological rationale is part of what makes PRP so appealing to both clinicians and patients. It is autologous, meaning it comes from your own body, which reduces the risk of allergic reactions or disease transmission. And the mechanism is intuitive: you are reintroducing a concentrated version of something your body already makes. Whether that intuitive appeal translates into consistent clinical results is another question entirely.

Knee Osteoarthritis, the Most Studied Indication

More clinical research has been done on PRP for knee osteoarthritis than for almost any other condition, and the picture is genuinely mixed. A retrospective study found that about 62% of patients met established criteria for a meaningful response after PRP injections, with better results in mild and moderate arthritis (roughly 75% and 67% responder rates, respectively) than in severe cases, where the rate dropped to about 51%.

⁵

Head-to-head comparisons with hyaluronic acid injections, a more conventional treatment, have generally favored PRP. One study tracking patients for a year found that the PRP group maintained significantly better pain scores, walking distance, and functional scores at every follow-up point compared to the hyaluronic acid group.

⁶

Yet a broader review of the evidence concluded that the effectiveness of PRP injections for knee osteoarthritis “remains controversial,” though most recent publications do show short-term pain relief.

⁷

The severity of arthritis appears to matter a lot. If your knee has minimal cartilage loss, PRP seems more likely to help. If the joint is bone-on-bone, the response rates drop considerably. This makes intuitive sense: PRP may support tissue repair, but it cannot rebuild cartilage that is already gone.

What Clinical Guidelines Actually Recommend

Given the mixed evidence, professional medical organizations have been cautious. A systematic review of international clinical practice guidelines found that about 82% of guidelines were either uncertain about PRP or unable to make a formal recommendation for or against it in knee osteoarthritis. Two guidelines recommended against its use. None gave it a strong endorsement.

⁸

More recently, the American Academy of Physical Medicine and Rehabilitation convened a panel of experts who used a consensus process to develop guidance on PRP for knee osteoarthritis. The panel arrived at five evidence-based clinical recommendations and eleven best-practice suggestions supported by expert opinion and limited evidence.

⁹

The fact that a major medical organization felt the need to publish guidance at all reflects how common PRP use has become in clinical practice, even without formal FDA approval. The guidelines exist partly to bring some standardization to a treatment that clinicians are already using widely.

Tendon Injuries Tell a More Skeptical Story

PRP for tendon problems has been studied across a range of conditions, from tennis elbow and rotator cuff tendinopathy in the upper body to patellar tendinopathy and Achilles tendon issues in the lower body.

¹⁰

The evidence here is less encouraging than for knee arthritis. An umbrella review of multiple systematic reviews on PRP for chronic Achilles tendinopathy found that the predominant conclusion across the literature was no meaningful difference between PRP and control treatments for pain reduction or functional improvement. Some reviews reported modest short-term improvements in the first few weeks, but those benefits were neither large enough to matter clinically nor sustained over longer follow-up periods. The review concluded that current evidence does not support routine PRP use as a first-line treatment for chronic Achilles tendinopathy.

¹¹

This does not mean PRP never helps anyone with a tendon problem. Individual responses vary, and some tendon conditions may respond differently than others. But the pattern in the research is clear enough: for tendons, established conservative treatments like physical therapy, eccentric loading exercises, and activity modification remain the standard of care.

Hair Loss and Cosmetic Uses

PRP has carved out a growing niche in dermatology, particularly for androgenetic alopecia, the most common type of hair thinning. The growth factors in PRP act on stem cells in the hair follicle and stimulate the development of new follicles along with new blood vessel formation in the scalp. With limited FDA-approved options for hair loss, PRP has become an appealing alternative.

¹²

Several studies have shown that PRP can be used effectively for hair loss treatment, though the quality and size of trials varies.

¹³

PRP is also commonly combined with microneedling for facial skin rejuvenation, the treatment sometimes marketed as a “vampire facial.” In that context, the microneedling device itself may carry FDA clearance while the PRP applied alongside it does not have approval for cosmetic skin improvement.

¹⁴

Cosmetic PRP treatments share the same regulatory status as orthopedic ones. The devices are cleared; the specific cosmetic application is not approved. This is worth keeping in mind when evaluating marketing claims from clinics. A provider saying their PRP system is “FDA cleared” is technically accurate about the device, but it does not mean the FDA has reviewed or approved what the provider plans to do with the resulting product.

The Standardization Problem

One reason the clinical evidence for PRP is so inconsistent is that “PRP” is not a single, standardized product. Different preparation systems produce concentrates with different platelet counts, different amounts of white blood cells, and different volumes. A persistent debate in the field revolves around whether leukocyte-rich or leukocyte-poor formulations produce better results, and the evidence has not settled the question.

¹⁵

This variability makes it genuinely difficult to compare studies against each other. One trial’s PRP might have three times the platelet concentration of another’s. The number of injections, the interval between them, and the activation method all differ across clinics and protocols. When a systematic review pools data from these wildly different approaches, the signal can easily get lost in the noise. This is one of the main reasons professional guidelines remain cautious: it is hard to recommend a treatment when “the treatment” is not the same thing from one clinic to the next.

Safety Profile

The safety record of PRP is generally reassuring. Because it comes from the patient’s own blood, the risk of allergic reactions, disease transmission, or immune rejection is low. A systematic review and meta-analysis of PRP for osteoarthritis found that among 24 included studies, 11 reported adverse reactions after PRP injections, but most symptoms were mild and temporary, such as pain and swelling at the injection site. Only one study reported intense knee pain in two patients, and all adverse events resolved without lasting consequences. Very few patients dropped out of studies because of side effects.

¹⁶

That said, a broader literature review cataloging adverse events across PRP applications found reports of postoperative infections (the most common), inflammation, nodule development, and, in rare cases involving facial injections, blindness.

¹⁷

The infection risk underscores why clinic hygiene and injection technique matter. PRP itself is sterile when properly prepared, but any injection carries an infection risk if protocols are not followed carefully. The blindness cases, though extremely rare, were linked to facial injections where the product accidentally entered a blood vessel supplying the eye. These are procedure-related risks rather than risks inherent to PRP as a substance.

PRP and Other Biologic Treatments

PRP is not the only biologic option in regenerative medicine. Bone marrow aspirate concentrate (BMAC), which contains stem cells along with growth factors, is another product used for similar musculoskeletal conditions. While BMAC has generated promising results for cartilage, bone, and muscle repair, its clinical track record is shorter than PRP’s. The two products work through distinct mechanisms, and there is evidence that combining them may produce synergistic effects, with PRP serving as a natural growth medium for the stem cells in BMAC.

¹⁸

BMAC faces similar regulatory ambiguity. Like PRP, it is autologous and falls into a gray zone where the preparation devices can be cleared even though the specific clinical applications lack formal approval. The entire field of orthobiologics is, in a sense, operating ahead of the regulatory framework, which was designed primarily for mass-manufactured drugs and devices rather than personalized blood-derived products prepared at the point of care.

How PRP Ended Up Everywhere

PRP’s path from surgical theaters to strip-mall clinics has been remarkably fast. The first documented use of platelet-rich plasma in medicine was in cardiac surgery in 1987, where it served as an autologous blood transfusion source to reduce surgical blood loss. It spread to maxillofacial surgery in the early 1990s for mandibular reconstructions, then into dentistry by the late 1990s for dental implant integration and bone regeneration.

¹⁹

The jump to sports medicine, cosmetic dermatology, and sexual health happened more recently and was driven partly by high-profile athletes publicizing their PRP treatments and partly by the relatively low barrier to offering it. A physician needs only a centrifuge, some specialized kits, and a blood draw to produce PRP in the office. No special facility, no pharmaceutical supply chain, no pharmacy intermediary. That accessibility, combined with patient demand and the autologous safety profile, created the conditions for rapid adoption long before the clinical evidence caught up.

What to Ask Before Getting PRP

If you are considering PRP, a few practical questions are worth raising with your provider. First, ask which preparation system they use and what platelet concentration it produces. Not all systems are equivalent, and the answer gives you a sense of whether the provider is thoughtful about the product they are injecting. Second, ask what evidence supports PRP for your specific condition. The data for mild-to-moderate knee arthritis is meaningfully stronger than the data for, say, chronic Achilles tendinopathy. A provider who acknowledges the limits of the evidence is generally more trustworthy than one who promises results across the board.

Third, ask about the number of sessions and total cost. PRP is almost never a one-and-done treatment. Most protocols call for a series of injections spaced weeks apart, followed by possible maintenance sessions. Total costs can add up quickly without insurance coverage. Finally, understand that “FDA cleared” on a clinic’s website refers to the centrifuge or preparation kit, not to PRP as a treatment for your condition. That distinction is not a reason to avoid PRP, but it is a reason to approach marketing claims with a healthy skepticism and weigh the decision carefully against alternatives that have stronger regulatory and evidentiary backing.